Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Innoviva, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WALTHAM, MASS.--(BUSINESS WIRE)--PRIX GALIEN AWARD 2025.

INNOVIVA SPECIALTY THERAPEUTICS' ANTIMICROBIAL THERAPIES ZEVTERA AND XACDURO NOMINATED FOR THE 2025 PRIX GALIEN USA BEST PHARMACEUTICAL PRODUCT AWARD

ENTERED INTO SECURED CREDIT AGREEMENT WITH INNOVIVA FOR $15 MILLION MATURING IN 2029 ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE PHASE 1B/2A DISARM TRIAL FOR AP-SA02 LOS ANGELES , AUG. 12, 2025 /PRNEWSWIRE/ --ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE. SECOND QUARTER 2025 AND RECENT DEVELOPMENTS: ON AUGUST 11, 2025, ENTERED INTO A SECURED CREDIT AGREEMENT WITH INNOVIVA STRATEGIC OPPORTUNITIES LLC, A WHOLLY OWNED SUBSIDIARY OF INNOVIVA, INC., ARMATA'S LARGEST SHAREHOLDER, FOR A LOAN OF $15.0 MILLION THAT WILL MATURE ON JANUARY 11, 2029 PROCEEDS FROM THE NEW FINANCING TRANSACTION WILL BE USED TO CONTINUE TO ADVANCE DEVELOPMENT OFARMATA'S LEAD STAPHYLOCOCCUS AUREUS ("S.

ARMATA PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2025 RESULTS AND PROVIDES CORPORATE UPDATE

BURLINGAME, CALIF.--(BUSINESS WIRE)--INNOVIVA, INC. (NASDAQ: INVA) (INNOVIVA OR THE COMPANY), A DIVERSIFIED HOLDING COMPANY WITH A CORE ROYALTIES PORTFOLIO, A LEADING CRITICAL CARE AND INFECTIOUS DISEASE PLATFORM KNOWN AS INNOVIVA SPECIALTY THERAPEUTICS (IST), AND A PORTFOLIO OF STRATEGIC INVESTMENTS IN HEALTHCARE ASSETS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND HIGHLIGHTED SELECT CORPORATE PROGRESS AND ACHIEVEMENTS. INNOVIVA CONTINUED TO DELIVER I.

INNOVIVA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS; HIGHLIGHTS RECENT COMPANY PROGRESS

WALTHAM, MASS. & GENEVA--(BUSINESS WIRE)--INNOVIVA SPECIALTY THERAPEUTICS, INC., A SUBSIDIARY OF INNOVIVA, INC. (NASDAQ: INVA), IN COLLABORATION WITH THE GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP (GARDP), TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED PRIORITY REVIEW FOR THE NEW DRUG APPLICATION (NDA) FOR ZOLIFLODACIN, AN INVESTIGATIONAL FIRST-IN-CLASS, SINGLE DOSE, SPIROPYRIMIDINETRIONE ORAL ANTIBIOTIC FOR THE TREATMENT OF UNCOMPLICATED GONORRHEA IN.

FDA GRANTS PRIORITY REVIEW FOR ZOLIFLODACIN NEW DRUG APPLICATION FOR THE TREATMENT OF UNCOMPLICATED GONORRHEA AND ASSIGNS TARGET PDUFA DATE OF DECEMBER 15, 2025

WALTHAM, MASS. & GENEVA, SWITZERLAND--(BUSINESS WIRE)--INNOVIVA SPECIALTY THERAPEUTICS, INC., A SUBSIDIARY OF INNOVIVA, INC. (NASDAQ: INVA), IN COLLABORATION WITH THE GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP (GARDP), TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED ITS NEW DRUG APPLICATION (NDA) FOR ZOLIFLODACIN, THE INVESTIGATIONAL FIRST-IN-CLASS, SINGLE DOSE, SPIROPYRIMIDINETRIONE ORAL ANTIBIOTIC FOR THE TREATMENT OF UNCOMPLICATED GONORRHEA IN ADUL.

INNOVIVA SPECIALTY THERAPEUTICS RECEIVES FDA NEW DRUG APPLICATION ACCEPTANCE FOR ZOLIFLODACIN, A FIRST-IN-CLASS ORAL ANTIBIOTIC FOR UNCOMPLICATED GONORRHEA IN ADULTS

BURLINGAME, CALIF.--(BUSINESS WIRE)--INNOVIVA, INC. (NASDAQ: INVA) (INNOVIVA OR THE COMPANY), A DIVERSIFIED HOLDING COMPANY WITH A CORE ROYALTIES PORTFOLIO, A LEADING CRITICAL CARE AND INFECTIOUS DISEASE PLATFORM KNOWN AS INNOVIVA SPECIALTY THERAPEUTICS (IST), AND A PORTFOLIO OF STRATEGIC INVESTMENTS IN HEALTHCARE ASSETS, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES IN JUNE: GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE 2025 FORM.

INNOVIVA TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

WALTHAM, MASS.--(BUSINESS WIRE)--INNOVIVA SPECIALTY THERAPEUTICS, INC., A SUBSIDIARY OF INNOVIVA, INC. (NASDAQ: INVA), TODAY ANNOUNCED THE UNITED STATES COMMERCIAL AVAILABILITY OF ZEVTERA (CEFTOBIPROLE MEDOCARIL SODIUM FOR INJECTION), THE NEWEST ADDITION TO THE COMPANY'S GROWING ANTIBIOTIC PORTFOLIO. ZEVTERA IS THE ONLY U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVED ADVANCED-GENERATION CEPHALOSPORIN INDICATED TO TREAT ADULT PATIENTS WITH STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION (BACTEREMI.

ZEVTERA (CEFTOBIPROLE), AN ADVANCED-GENERATION CEPHALOSPORIN ANTIBIOTIC NOW COMMERCIALLY AVAILABLE IN THE U.S. TO TREAT THREE TYPES OF BACTERIAL INFECTIONS

ALLSCHWIL, SWITZERLAND, MAY 20, 2025 BASILEA PHARMACEUTICA LTD, ALLSCHWIL (SIX: BSLN), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO MEETING THE NEEDS OF PATIENTS WITH SEVERE BACTERIAL AND FUNGAL INFECTIONS, ANNOUNCED TODAY THAT ITS ANTIBIOTIC ZEVTERA (CEFTOBIPROLE MEDOCARIL FOR INJECTION) IS NOW COMMERCIALLY AVAILABLE IN THE UNITED STATES THROUGH BASILEA'S PARTNER INNOVIVA SPECIALTY THERAPEUTICS, INC., A WHOLLY OWNED SUBSIDIARY OF INNOVIVA, INC. (NASDAQ: INVA). ZEVTERA IS USED IN HOSPITALS FOR THE TREATMENT OF BACTERIAL INFECTIONS, SUCH AS THOSE CAUSED BY STAPHYLOCOCCUS AUREUS BACTERIA, INCLUDING METHICILLIN-RESISTANT STRAINS (MRSA).

BASILEA ANNOUNCES COMMERCIAL AVAILABILITY OF ANTIBIOTIC ZEVTERA (CEFTOBIPROLE) IN THE UNITED STATES

PROCEEDS TO BE USED TO CONTINUE TO ADVANCE DEVELOPMENT OFARMATA'S PHAGE PRODUCT CANDIDATES LOS ANGELES , MARCH 12, 2025 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURED CREDIT AGREEMENT WITH INNOVIVA STRATEGIC OPPORTUNITIES LLC, A WHOLLY-OWNED SUBSIDIARY OF INNOVIVA, INC. (NASDAQ: INVA) (COLLECTIVELY, "INNOVIVA"), ARMATA'S LARGEST SHAREHOLDER. THE GROSS PROCEEDS TO BE RECEIVED BY THE COMPANY AT CLOSING ARE $10 MILLION BEFORE DEDUCTING TRANSACTION-RELATED EXPENSES.

ARMATA PHARMACEUTICALS ANNOUNCES $10 MILLION SECURED CREDIT AGREEMENT WITH INNOVIVA

BURLINGAME, CALIF.--(BUSINESS WIRE)--INNOVIVA, INC. (NASDAQ: INVA) (INNOVIVA OR THE COMPANY), A DIVERSIFIED HOLDING COMPANY WITH A CORE ROYALTIES PORTFOLIO, A LEADING CRITICAL CARE AND INFECTIOUS DISEASE PLATFORM KNOWN AS INNOVIVA SPECIALTY THERAPEUTICS (IST), AND A PORTFOLIO OF STRATEGIC INVESTMENTS IN HEALTHCARE ASSETS, TODAY ANNOUNCED THAT PAVEL RAIFELD, CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE BARCLAYS 27TH ANNUAL GLOBAL HEALTHCARE CONFERENCE IN MIAMI, FL ON.

INNOVIVA TO PARTICIPATE IN THE BARCLAYS 27TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

BURLINGAME, CALIF.--(BUSINESS WIRE)--INNOVIVA, INC. (NASDAQ: INVA) (INNOVIVA OR THE COMPANY), A DIVERSIFIED HOLDING COMPANY WITH A CORE ROYALTIES PORTFOLIO, A LEADING CRITICAL CARE AND INFECTIOUS DISEASE PLATFORM KNOWN AS INNOVIVA SPECIALTY THERAPEUTICS (IST), AND A PORTFOLIO OF STRATEGIC INVESTMENTS IN HEALTHCARE ASSETS, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2024, AND HIGHLIGHTED SELECT CORPORATE PROGRESS AND ACHIEVEMENTS. PAVEL RAIFELD,.

INNOVIVA REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS; HIGHLIGHTS RECENT COMPANY PROGRESS

BURLINGAME, CALIF.--(BUSINESS WIRE)--INNOVIVA, INC. (NASDAQ: INVA) (INNOVIVA OR THE COMPANY), A DIVERSIFIED HOLDING COMPANY WITH A CORE ROYALTIES PORTFOLIO, A LEADING CRITICAL CARE AND INFECTIOUS DISEASE PLATFORM KNOWN AS INNOVIVA SPECIALTY THERAPEUTICS (IST), AND A PORTFOLIO OF STRATEGIC INVESTMENTS IN HEALTHCARE ASSETS, TODAY ANNOUNCED THAT PAVEL RAIFELD, CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A PODIUM PRESENTATION AT THE OPPENHEIMER 35TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE.

Innoviva, Inc.

INVA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Innoviva, Inc.

INVA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

INVA